Cdc7 and Mcm2 expression as markers for the proliferation and prognosis of diffuse large B cell lymphoma

Yaxuan Wang, Huaqing Wang, Kai Fu, Yun Hou, Huilai Zhang, Zhengzi Qian, Shiyong Zhou, Lihua Qiu

Research output: Contribution to journalArticle

Abstract

Objective: To assess the proliferative activity of diffuse large B cell lymphoma (DLBCL) using immunohistochemistry (IHC) and real-time polymerase chain reaction of Cdc7 and Mcm2 and to explore their potential value in predicting prognosis. Methods: From Jan 2008 to Jan 2010, the clinical characteristics of 60 DLBCL patients were collected using IHC to assess the expression of Cdc7 and Mcm2. A statistical analysis was conducted on the association of Cdc7 and Mcm2 with the clinicopathologic characteristics of DLBCLs. Results: In the univariate analysis, the 2-year overall survival rate of the patients with positive Cdc7 expression was 41%, and the patient with negative Cdc7 expression was 73%, (P < 0.05). The 2-year overall survival rate of the patients with positive Mcm2 expression was 25%, and the patients with negative Mcm2 expression was 75% (P < 0.05). The clinical data were as follows: ECOG performance status (0-1 vs. 2) (76.6% vs. 23.4%); Ann Arbor stage (I-II vs. III-IV) (65.0% vs. 35.0%); IPI (0-1 vs. ≥ 2) ( 78.3% vs. 21.7%); LDH level (normal vs. abnormal) (70.0% vs. 30.3%); radiotherapy only vs. chemotherapy combined with radiotherapy (41.7% vs. 58.3%); and GCB subtype vs. non-GCB subtype (53.3% vs. 46.7%). ECOG performance status, Ann Arbor stage, International prognostic index (IPI), LDH level, therapy model, and histological type were found to be the prognostic factors associated with the overall survival in DLBCL. The difference in 2-year overall survival rates between the different clinical indicators were significant. The patients with Cdc7- and Mcm2-positive DLBCL had a higher stage of disease than patients with Cdc7- and Mcm2-negative DLBCL. The patients with Cdc7- and Mcm2-positive DLBCL had higher IPI of disease than patients with Cdc7- and Mcm2-negative DLBCL. Conclusion: IPI, treatment, and different cell derivation were prognostic factors. Furthermore, poor disease specific survival is observed in DLBCL patients with high-level Cdc7 and Mcm2 expression.

Original languageEnglish (US)
Pages (from-to)1088-1091
Number of pages4
JournalChinese Journal of Clinical Oncology
Volume38
Issue number18
DOIs
StatePublished - Sep 30 2011

Fingerprint

Lymphoma, Large B-Cell, Diffuse
Survival Rate
Radiotherapy
Immunohistochemistry
Survival
Real-Time Polymerase Chain Reaction
Drug Therapy

Keywords

  • Cdc7
  • Diffuse large B cell lymphoma
  • Mcm2
  • Prognostic factors

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Cdc7 and Mcm2 expression as markers for the proliferation and prognosis of diffuse large B cell lymphoma. / Wang, Yaxuan; Wang, Huaqing; Fu, Kai; Hou, Yun; Zhang, Huilai; Qian, Zhengzi; Zhou, Shiyong; Qiu, Lihua.

In: Chinese Journal of Clinical Oncology, Vol. 38, No. 18, 30.09.2011, p. 1088-1091.

Research output: Contribution to journalArticle

Wang, Yaxuan ; Wang, Huaqing ; Fu, Kai ; Hou, Yun ; Zhang, Huilai ; Qian, Zhengzi ; Zhou, Shiyong ; Qiu, Lihua. / Cdc7 and Mcm2 expression as markers for the proliferation and prognosis of diffuse large B cell lymphoma. In: Chinese Journal of Clinical Oncology. 2011 ; Vol. 38, No. 18. pp. 1088-1091.
@article{ed3d0a5f82e6448aa3e361cde41b043b,
title = "Cdc7 and Mcm2 expression as markers for the proliferation and prognosis of diffuse large B cell lymphoma",
abstract = "Objective: To assess the proliferative activity of diffuse large B cell lymphoma (DLBCL) using immunohistochemistry (IHC) and real-time polymerase chain reaction of Cdc7 and Mcm2 and to explore their potential value in predicting prognosis. Methods: From Jan 2008 to Jan 2010, the clinical characteristics of 60 DLBCL patients were collected using IHC to assess the expression of Cdc7 and Mcm2. A statistical analysis was conducted on the association of Cdc7 and Mcm2 with the clinicopathologic characteristics of DLBCLs. Results: In the univariate analysis, the 2-year overall survival rate of the patients with positive Cdc7 expression was 41{\%}, and the patient with negative Cdc7 expression was 73{\%}, (P < 0.05). The 2-year overall survival rate of the patients with positive Mcm2 expression was 25{\%}, and the patients with negative Mcm2 expression was 75{\%} (P < 0.05). The clinical data were as follows: ECOG performance status (0-1 vs. 2) (76.6{\%} vs. 23.4{\%}); Ann Arbor stage (I-II vs. III-IV) (65.0{\%} vs. 35.0{\%}); IPI (0-1 vs. ≥ 2) ( 78.3{\%} vs. 21.7{\%}); LDH level (normal vs. abnormal) (70.0{\%} vs. 30.3{\%}); radiotherapy only vs. chemotherapy combined with radiotherapy (41.7{\%} vs. 58.3{\%}); and GCB subtype vs. non-GCB subtype (53.3{\%} vs. 46.7{\%}). ECOG performance status, Ann Arbor stage, International prognostic index (IPI), LDH level, therapy model, and histological type were found to be the prognostic factors associated with the overall survival in DLBCL. The difference in 2-year overall survival rates between the different clinical indicators were significant. The patients with Cdc7- and Mcm2-positive DLBCL had a higher stage of disease than patients with Cdc7- and Mcm2-negative DLBCL. The patients with Cdc7- and Mcm2-positive DLBCL had higher IPI of disease than patients with Cdc7- and Mcm2-negative DLBCL. Conclusion: IPI, treatment, and different cell derivation were prognostic factors. Furthermore, poor disease specific survival is observed in DLBCL patients with high-level Cdc7 and Mcm2 expression.",
keywords = "Cdc7, Diffuse large B cell lymphoma, Mcm2, Prognostic factors",
author = "Yaxuan Wang and Huaqing Wang and Kai Fu and Yun Hou and Huilai Zhang and Zhengzi Qian and Shiyong Zhou and Lihua Qiu",
year = "2011",
month = "9",
day = "30",
doi = "10.3969/j.issn.1000-8179.2011.18.008",
language = "English (US)",
volume = "38",
pages = "1088--1091",
journal = "Chinese Journal of Clinical Oncology",
issn = "1672-7118",
publisher = "China Anti-Cancer Association",
number = "18",

}

TY - JOUR

T1 - Cdc7 and Mcm2 expression as markers for the proliferation and prognosis of diffuse large B cell lymphoma

AU - Wang, Yaxuan

AU - Wang, Huaqing

AU - Fu, Kai

AU - Hou, Yun

AU - Zhang, Huilai

AU - Qian, Zhengzi

AU - Zhou, Shiyong

AU - Qiu, Lihua

PY - 2011/9/30

Y1 - 2011/9/30

N2 - Objective: To assess the proliferative activity of diffuse large B cell lymphoma (DLBCL) using immunohistochemistry (IHC) and real-time polymerase chain reaction of Cdc7 and Mcm2 and to explore their potential value in predicting prognosis. Methods: From Jan 2008 to Jan 2010, the clinical characteristics of 60 DLBCL patients were collected using IHC to assess the expression of Cdc7 and Mcm2. A statistical analysis was conducted on the association of Cdc7 and Mcm2 with the clinicopathologic characteristics of DLBCLs. Results: In the univariate analysis, the 2-year overall survival rate of the patients with positive Cdc7 expression was 41%, and the patient with negative Cdc7 expression was 73%, (P < 0.05). The 2-year overall survival rate of the patients with positive Mcm2 expression was 25%, and the patients with negative Mcm2 expression was 75% (P < 0.05). The clinical data were as follows: ECOG performance status (0-1 vs. 2) (76.6% vs. 23.4%); Ann Arbor stage (I-II vs. III-IV) (65.0% vs. 35.0%); IPI (0-1 vs. ≥ 2) ( 78.3% vs. 21.7%); LDH level (normal vs. abnormal) (70.0% vs. 30.3%); radiotherapy only vs. chemotherapy combined with radiotherapy (41.7% vs. 58.3%); and GCB subtype vs. non-GCB subtype (53.3% vs. 46.7%). ECOG performance status, Ann Arbor stage, International prognostic index (IPI), LDH level, therapy model, and histological type were found to be the prognostic factors associated with the overall survival in DLBCL. The difference in 2-year overall survival rates between the different clinical indicators were significant. The patients with Cdc7- and Mcm2-positive DLBCL had a higher stage of disease than patients with Cdc7- and Mcm2-negative DLBCL. The patients with Cdc7- and Mcm2-positive DLBCL had higher IPI of disease than patients with Cdc7- and Mcm2-negative DLBCL. Conclusion: IPI, treatment, and different cell derivation were prognostic factors. Furthermore, poor disease specific survival is observed in DLBCL patients with high-level Cdc7 and Mcm2 expression.

AB - Objective: To assess the proliferative activity of diffuse large B cell lymphoma (DLBCL) using immunohistochemistry (IHC) and real-time polymerase chain reaction of Cdc7 and Mcm2 and to explore their potential value in predicting prognosis. Methods: From Jan 2008 to Jan 2010, the clinical characteristics of 60 DLBCL patients were collected using IHC to assess the expression of Cdc7 and Mcm2. A statistical analysis was conducted on the association of Cdc7 and Mcm2 with the clinicopathologic characteristics of DLBCLs. Results: In the univariate analysis, the 2-year overall survival rate of the patients with positive Cdc7 expression was 41%, and the patient with negative Cdc7 expression was 73%, (P < 0.05). The 2-year overall survival rate of the patients with positive Mcm2 expression was 25%, and the patients with negative Mcm2 expression was 75% (P < 0.05). The clinical data were as follows: ECOG performance status (0-1 vs. 2) (76.6% vs. 23.4%); Ann Arbor stage (I-II vs. III-IV) (65.0% vs. 35.0%); IPI (0-1 vs. ≥ 2) ( 78.3% vs. 21.7%); LDH level (normal vs. abnormal) (70.0% vs. 30.3%); radiotherapy only vs. chemotherapy combined with radiotherapy (41.7% vs. 58.3%); and GCB subtype vs. non-GCB subtype (53.3% vs. 46.7%). ECOG performance status, Ann Arbor stage, International prognostic index (IPI), LDH level, therapy model, and histological type were found to be the prognostic factors associated with the overall survival in DLBCL. The difference in 2-year overall survival rates between the different clinical indicators were significant. The patients with Cdc7- and Mcm2-positive DLBCL had a higher stage of disease than patients with Cdc7- and Mcm2-negative DLBCL. The patients with Cdc7- and Mcm2-positive DLBCL had higher IPI of disease than patients with Cdc7- and Mcm2-negative DLBCL. Conclusion: IPI, treatment, and different cell derivation were prognostic factors. Furthermore, poor disease specific survival is observed in DLBCL patients with high-level Cdc7 and Mcm2 expression.

KW - Cdc7

KW - Diffuse large B cell lymphoma

KW - Mcm2

KW - Prognostic factors

UR - http://www.scopus.com/inward/record.url?scp=80855124853&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80855124853&partnerID=8YFLogxK

U2 - 10.3969/j.issn.1000-8179.2011.18.008

DO - 10.3969/j.issn.1000-8179.2011.18.008

M3 - Article

VL - 38

SP - 1088

EP - 1091

JO - Chinese Journal of Clinical Oncology

JF - Chinese Journal of Clinical Oncology

SN - 1672-7118

IS - 18

ER -